Prasugrel
- Generic Name
- Prasugrel
- Brand Names
- Effient, Efient, Prasugrel Viatris (previously Prasugrel Mylan)
- Drug Type
- Small Molecule
- Chemical Formula
- C20H20FNO3S
- CAS Number
- 150322-43-3
- Unique Ingredient Identifier
- 34K66TBT99
- Background
Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversibly binds to P2Y12 type ADP receptors on platelets thus preventing activation of the GPIIb/IIIa receptor complex. As a result, inhibition of ADP-mediated platelet activation and aggregation occurs. Prasugrel was developed by Daiichi Sankyo Co. and is currently marketed in the United States and Canada in cooperation with Eli Lilly and Company for acute coronary syndromes planned for percutaneous coronary intervention (PCI). FDA approved in 2009.
- Indication
用于心力衰竭、卒中、不稳定心绞痛等心脑血管疾病以及有急性冠状动脉综合征需要进行经皮冠脉介入术的患者。
- Associated Conditions
- Cardiovascular Events
Antiplatelet Therapy Guided by Thrombelastography in Patients With Acute Coronary Syndromes (TEGCOR Study)
- Conditions
- ThrombosisCoronary Artery Disease
- Interventions
- First Posted Date
- 2012-06-06
- Last Posted Date
- 2018-04-26
- Lead Sponsor
- Indiana University
- Target Recruit Count
- 67
- Registration Number
- NCT01612884
- Locations
- 🇺🇸
Eskenazi Health, Indianapolis, Indiana, United States
🇺🇸Indiana University Health Methodist Hospital, Indianapolis, Indiana, United States
Reloading Prasugrel or Clopidogrel on High Platelet Reactivity Before Percutaneous Coronary Intervention
- First Posted Date
- 2012-06-01
- Last Posted Date
- 2014-12-23
- Lead Sponsor
- Dong-A University
- Target Recruit Count
- 76
- Registration Number
- NCT01609647
- Locations
- 🇰🇷
DongA University Hospital, Busan, Korea, Republic of
The Effect Of Antiplatelets Therapy On Saphenous Vein Coronary Artery Bypass Graft Patency
- Conditions
- Coronary Artery Disease
- Interventions
- First Posted Date
- 2012-05-15
- Last Posted Date
- 2012-05-15
- Lead Sponsor
- Prince Sultan Cardiac Center, Adult Cardiology Department.
- Target Recruit Count
- 200
- Registration Number
- NCT01598337
- Locations
- 🇸🇦
Prince Sultan Cardiac Center, Riyadh, Saudi Arabia
Therapeutic Control of Aspirin-Exacerbated Respiratory Disease (Aspirin)
- Conditions
- Asthma, Aspirin-InducedAspirin Exacerbated Asthma
- Interventions
- Drug: Placebo Oral Tablet
- First Posted Date
- 2012-05-14
- Last Posted Date
- 2019-09-19
- Lead Sponsor
- Elliot Israel, MD
- Target Recruit Count
- 46
- Registration Number
- NCT01597375
- Locations
- 🇺🇸
Asthma Research Center, Boston, Massachusetts, United States
Study of Prasugrel in Korean Healthy Male Volunteers
- First Posted Date
- 2012-05-04
- Last Posted Date
- 2012-10-04
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 30
- Registration Number
- NCT01591317
- Locations
- 🇰🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seoul, Korea, Republic of
Pharmacodynamic Evaluation of Switching From Ticagrelor to Prasugrel in Subjects With Stable Coronary Artery Disease
- Conditions
- Coronary Artery Disease
- Interventions
- First Posted Date
- 2012-04-30
- Last Posted Date
- 2019-01-09
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 110
- Registration Number
- NCT01587651
- Locations
- 🇺🇸
Sinai Center for Thrombosis Research, Baltimore, Maryland, United States
🇺🇸Clinical Pharmacology Unit of Miami, Miami, Florida, United States
🇺🇸Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States
Prasugrel for Prevention of Early Saphenous Vein Graft Thrombosis
- First Posted Date
- 2012-03-22
- Last Posted Date
- 2019-10-30
- Lead Sponsor
- VA Office of Research and Development
- Target Recruit Count
- 84
- Registration Number
- NCT01560780
- Locations
- 🇺🇸
Jesse Brown VA Medical Center Community-Based Outpatient Clinic Lake Side Divison, Chicago, IL, Chicago, Illinois, United States
🇺🇸North Florida/South Georgia Veterans Health System, Gainesville, FL, Gainesville, Florida, United States
🇺🇸San Francisco VA Medical Center, San Francisco, CA, San Francisco, California, United States
High Clopidogrel Dose Versus Prasugrel and Ticagrelor in High Reactive Stable Patients
- Conditions
- Coronary Artery Disease
- Interventions
- First Posted Date
- 2012-03-05
- Last Posted Date
- 2013-12-11
- Lead Sponsor
- University of Roma La Sapienza
- Target Recruit Count
- 81
- Registration Number
- NCT01543932
- Locations
- 🇮🇹
Dept.of Cardiovascular Sciences,Policlinico Umberto I, Rome, Italy
Tailored Antiplatelet Therapy Versus Recommended Dose of Prasugrel
- Conditions
- Acute Coronary Syndrome
- Interventions
- Drug: Modification of Prasugrel based on a biological assayDevice: Verify Now
- First Posted Date
- 2012-02-24
- Last Posted Date
- 2017-01-11
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 880
- Registration Number
- NCT01538446
- Locations
- 🇫🇷
CHU Caremeau à Nimes - Service de Cardiologie, Nimes, France
🇫🇷ACTION study group - Institut de Cardiologie- Hôpital la Pitié Salpêtrière, Paris, France
PraSugrel vs TicagrElor in ST-Elevation Myocardial Infarction paTients With Diabetes Mellitus
- Conditions
- ST-Elevation Myocardial Infarction
- Interventions
- First Posted Date
- 2012-02-10
- Last Posted Date
- 2017-06-28
- Lead Sponsor
- Gennaro Sardella
- Target Recruit Count
- 50
- Registration Number
- NCT01531114
- Locations
- 🇮🇹
Dept.of Cardiovascular Sciences,Policlinico Umberto I, Rome, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.